Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
HS&M Magazine
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
TAVALISSE
HSMN NewsFeed - 15 Nov 2021
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Biopharmaceuticals
HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 18 Feb 2021
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Biopharmaceuticals
Licensing
HSMN NewsFeed - 23 Nov 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 15 Nov 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 18 May 2018
Apexigen Expands Leadership Team With Appointment Of Frances Rena Bahjat, Ph.D. Vice President, Discovery Research
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 25 Aug 2017
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Biopharmaceuticals
Personnel
HSMN NewsFeed - 19 Jun 2017
FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
Biopharmaceuticals
FDA
HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Biopharmaceuticals
Oncology
Return to NewsFeed